- Home
- ARCO vs SUPN Comparison
ARCO vs SUPN Comparison
Compare ARCO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCO
- SUPN
- Stock Information
- Founded
- ARCO 2007
- SUPN 2005
- Country
- ARCO Uruguay
- SUPN United States
- Employees
- ARCO N/A
- SUPN N/A
- Industry
- ARCO Restaurants
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- ARCO Consumer Discretionary
- SUPN Health Care
- Exchange
- ARCO Nasdaq
- SUPN Nasdaq
- Market Cap
- ARCO 2.1B
- SUPN 1.9B
- IPO Year
- ARCO 2011
- SUPN 2012
- Fundamental
- Price
- ARCO $8.33
- SUPN $35.82
- Analyst Decision
- ARCO Strong Buy
- SUPN Hold
- Analyst Count
- ARCO 2
- SUPN 1
- Target Price
- ARCO $13.50
- SUPN $36.00
- AVG Volume (30 Days)
- ARCO 1.1M
- SUPN 425.0K
- Earning Date
- ARCO 11-13-2024
- SUPN 11-04-2024
- Dividend Yield
- ARCO 2.87%
- SUPN N/A
- EPS Growth
- ARCO N/A
- SUPN 130.79
- EPS
- ARCO 0.69
- SUPN 1.07
- Revenue
- ARCO $4,501,397,000.00
- SUPN $651,972,000.00
- Revenue This Year
- ARCO $5.50
- SUPN $7.82
- Revenue Next Year
- ARCO $8.03
- SUPN N/A
- P/E Ratio
- ARCO $12.35
- SUPN $33.77
- Revenue Growth
- ARCO 7.82
- SUPN 6.79
- 52 Week Low
- ARCO $8.07
- SUPN $25.53
- 52 Week High
- ARCO $13.20
- SUPN $39.37
- Technical
- Relative Strength Index (RSI)
- ARCO 38.55
- SUPN 54.35
- Support Level
- ARCO $8.07
- SUPN $34.86
- Resistance Level
- ARCO $8.87
- SUPN $39.37
- Average True Range (ATR)
- ARCO 0.28
- SUPN 1.71
- MACD
- ARCO -0.01
- SUPN -0.16
- Stochastic Oscillator
- ARCO 31.48
- SUPN 40.24
About ARCO Arcos Dorados Holdings Inc. Shares
Arcos Dorados Holdings Inc operates McDonald's-branded restaurants in approximately 20 countries and territories in Latin America and the Caribbean. It functions through two sources which include company-operated restaurants and franchised restaurants segment. Their menu includes hamburgers, McNuggets, salad, sandwiches, french fries and others.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.